Info

🌱 來自: management of metastatic disease-of-bladder cancer

2nd line of metastatic disease-of-bladder cancer

• FDA-approved agents include pembrolizumab a/w ↑ OS vs. chemo (NEJM 2017;376:1015), nivolumab a/w 24% RR (Lancet Onc 2016;17:1590), avelumab a/w 17% RR (Lancet Onc 2018;19:51). If FGFR2/3 genetic alterations, erdafitinib can be used post platinum, a/w 40% RR (NEJM 2019;381:338), but usually deferred until 3rd or 4th line